Prospect of Vasoactive Intestinal Peptide Therapy for COPD/PAH and Asthma: a Review

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2011 Apr 12

PMID 21477377

Citations 20

Authors

Dongmei Wu

Dongwon Lee

Yong Kiel Sung

Affiliations

Soon will be listed here.

Abstract

There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons, including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.

Citing Articles

Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use.

Ilina Y, Kaufmann P, Press M, Uba T, Bergmann A Biomolecules. 2025; 15(2).

PMID: 40001527 PMC: 11853079. DOI: 10.3390/biom15020224.

spp. utilize the type 3 secretion system to manipulate the VIP/VPAC2 signaling and promote colonization and persistence of the three classical in the lower respiratory tract.

First N, Pedreira-Lopez J, San-Silvestre M, Parrish K, Lu X, Gestal M Front Cell Infect Microbiol. 2023; 13:1111502.

PMID: 37065208 PMC: 10090565. DOI: 10.3389/fcimb.2023.1111502.

Triple-tyrosine kinase inhibition by BIBF1000 attenuates airway and pulmonary arterial remodeling following chronic allergen challenges in mice.

Gurusamy M, Nasseri S, Rampa D, Feng H, Lee D, Pekcec A Eur J Med Res. 2023; 28(1):71.

PMID: 36755351 PMC: 9909896. DOI: 10.1186/s40001-023-01037-2.

Potential cellular endocrinology mechanisms underlying the effects of Chinese herbal medicine therapy on asthma.

Meng Z, Chen H, Deng C, Meng S Front Endocrinol (Lausanne). 2022; 13:916328.

PMID: 36051395 PMC: 9424672. DOI: 10.3389/fendo.2022.916328.

A distinctive ligand recognition mechanism by the human vasoactive intestinal polypeptide receptor 2.

Xu Y, Feng W, Zhou Q, Liang A, Li J, Dai A Nat Commun. 2022; 13(1):2272.

PMID: 35477937 PMC: 9046186. DOI: 10.1038/s41467-022-30041-z.

References

Lucia P, Caiola S, Coppola A, Maroccia E, Belli M, Buongiorno A . Early increase of vasoactive intestinal peptide in acute myocardial infarction. Am Heart J. 1996; 132(1 Pt 1):187-9. DOI: 10.1016/s0002-8703(96)90408-1. View

Misaka S, Sato H, Aoki Y, Mizumoto T, Onoue S, Yamada S . Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis. Peptides. 2010; 32(2):401-7. DOI: 10.1016/j.peptides.2010.10.021. View

Dey R, Shannon Jr W, Said S . Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res. 1981; 220(2):231-8. DOI: 10.1007/BF00210505. View

Metwali A, Blum A, Ferraris L, Klein J, Fiocchi C, Weinstock J . Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol. 1994; 52(1):69-78. DOI: 10.1016/0165-5728(94)90164-3. View

Goetzl E, Voice J, Shen S, Dorsam G, Kong Y, West K . Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A. 2001; 98(24):13854-9. PMC: 61131. DOI: 10.1073/pnas.241503798. View

Henning R . Vagal stimulation during muscarinic and beta-adrenergic blockade increases atrial contractility and heart rate. J Auton Nerv Syst. 1992; 40(2):121-9. DOI: 10.1016/0165-1838(92)90023-a. View

Said S, Mutt V, Yoshida T, Hara N . Vasoactive polypeptides from normal lung. Chest. 1975; 67(2 Suppl):44S. DOI: 10.1016/s0012-3692(15)53085-7. View

Gyongyosi M, Nemeth J, Varkonyi T . Elevated levels of plasma vasoactive intestinal peptide in human acute myocardial infarction. Int J Cardiol. 1996; 56(2):159-61. View

Mannino D, Buist A . Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370(9589):765-73. DOI: 10.1016/S0140-6736(07)61380-4. View

10.

Coles S, Said S, Reid L . Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro. Am Rev Respir Dis. 1981; 124(5):531-6. DOI: 10.1164/arrd.1981.124.5.531. View

11.

Kuncova J, Slavikova J, Reischig J . Distribution of vasoactive intestinal polypeptide in the rat heart: effect of guanethidine and capsaicin. Ann Anat. 2003; 185(2):153-61. DOI: 10.1016/S0940-9602(03)80079-1. View

12.

Haberl I, Frei K, Ramsebner R, Doberer D, Petkov V, Albinni S . Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. Eur J Hum Genet. 2006; 15(1):18-22. DOI: 10.1038/sj.ejhg.5201711. View

13.

ODorisio M, ODorisio T, Cataland S, Balcerzak S . Vasoactive intestinal polypeptide as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med. 1980; 96(4):666-72. View

14.

Said S, Hamidi S, Gonzalez Bosc L . Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?. Eur Respir J. 2010; 35(4):730-4. PMC: 2963099. DOI: 10.1183/09031936.00097109. View

15.

Berisha H, FODA H, Sakakibara H, Trotz M, Pakbaz H, Said S . Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase. Am J Physiol. 1990; 259(2 Pt 1):L151-5. DOI: 10.1152/ajplung.1990.259.2.L151. View

16.

Fischer A, Canning B, Undem B, Kummer W . Evidence for an esophageal origin of VIP-IR and NO synthase-IR nerves innervating the guinea pig trachealis: a retrograde neuronal tracing and immunohistochemical analysis. J Comp Neurol. 1998; 394(3):326-34. View

17.

Frase L, Gaffney F, Lane L, Buckey J, Said S, Blomqvist C . Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol. 1987; 60(16):1356-61. DOI: 10.1016/0002-9149(87)90619-9. View

18.

Slavikova J . Distribution of peptide-containing neurons in the developing rat right atrium, studied using immunofluorescence and confocal laser scanning. Neurochem Res. 1997; 22(8):1013-21. DOI: 10.1023/a:1022431011019. View

19.

Colston J, Freeman G . Beneficial influence of vasoactive intestinal peptide on ventriculovascular coupling in closed-chest dogs. Am J Physiol. 1992; 263(4 Pt 2):H1300-5. DOI: 10.1152/ajpheart.1992.263.4.H1300. View

20.

Luts A, Sundler F . Peptide-containing nerve fibers in the respiratory tract of the ferret. Cell Tissue Res. 1989; 258(2):259-67. DOI: 10.1007/BF00239446. View